Widely used:Recently Viewed
Clear All
Value Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹14,563 Cr
P/E Ratio
23.22
P/B Ratio
2.41
Industry P/E
34.17
Debt to Equity
0.63
ROE
1.34 %
ROCE
5.02 %
Div. Yield
0.55 %
Book Value
379.31
EPS
27.83
CFO
₹11,372.09 Cr
EBITDA
₹12,328.91 Cr
Net Profit
₹3,805.16 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
| -17.12 | 1.89 | -6.74 | 37.74 | 24.26 | 43.11 | 28.84 |
|
BSE Healthcare
| -7.08 | 1.19 | -2.36 | 21.92 | 19.22 | 23.01 | 9.35 |
|
BSE Mid Cap
| -7.51 | 3.73 | -2.60 | 7.25 | 20.44 | 29.46 | 15.06 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Jubilant Pharmova
| 90.50 | 45.55 | -36.11 | -31.13 | 58.62 | -24.59 | -8.62 |
|
BSE Mid Cap
| 25.84 | 45.53 | 1.38 | 39.18 | 19.87 | -3.05 | -13.31 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 1,368.80 | 38,633.29 | -- | -15.04 | |
| 640.35 | 34,525.64 | 172.4 | 4.86 | |
| 1,202.20 | 30,727.26 | 110.04 | 13.86 | |
| 724.60 | 29,177.89 | 58.18 | 11.04 |
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables,... Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. The Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom immunotherapy products. The CDMO Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. The Generics segment engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The CRDMO segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune diseases. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India. Read more
Incorporated
1978
Chairman
Shyam S Bhartia
Managing Director
Priyavrat Bhartia
Group
Jubilant Bhartia
Headquarters
Gajraula, Uttar Pradesh
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsRumour verification - Regulation 30(11)
25-Feb-2025Audio Recording Of Investors / Analysts Meeting
24-Feb-2025Presentation For Investor And Analyst Meet
24-Feb-2025
The total asset value of Jubilant Pharmova Ltd stood at ₹ 11,924 Cr as on 31-Dec-24
The share price of Jubilant Pharmova Ltd is ₹915.95 (NSE) and ₹914.30 (BSE) as of 21-Apr-2025 IST. Jubilant Pharmova Ltd has given a return of 24.26% in the last 3 years.
Jubilant Pharmova Ltd has a market capitalisation of ₹ 14,563 Cr as on 21-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Jubilant Pharmova Ltd is 2.41 times as on 21-Apr-2025, a 35% discount to its peers’ median range of 3.71 times.
The P/E ratio of Jubilant Pharmova Ltd is 23.22 times as on 21-Apr-2025, a 32% discount to its peers’ median range of 34.17 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Jubilant Pharmova Ltd and enter the required number of quantities and click on buy to purchase the shares of Jubilant Pharmova Ltd.
Jubilant Pharmova Limited operates as an integrated pharmaceutical and life sciences company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Generics, Contract Research Development & Manufacturing Organisation (CRDMO), and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. The Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom immunotherapy products. The CDMO Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. The Generics segment engages in the development, manufacturing, distribution, sale, and marketing of solid dosage formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, and multispecialty. The CRDMO segment offers drug discovery and development services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune diseases. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. Jubilant Pharmova Limited was incorporated in 1978 and is based in Noida, India.
The promoters of Jubilant Pharmova Ltd are SPB TRUSTEE COMPANY PVT LTD and HSB TRUSTEE COMPANY PVT LTD. They collectively own 39.52 per cent of the total equity. The chairman of the company is Shyam S Bhartia
There is no promoter pledging in Jubilant Pharmova Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
37,861
|
|
|
33,830
|
|
|
29,729
|
|
|
29,268
|
| Jubilant Pharmova Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
7.79
|
|
Operating margin(%)
|
10.27
|
|
Net Margin(%)
|
8.71
|
|
Dividend yield(%)
|
0.55
|
Yes, TTM profit after tax of Jubilant Pharmova Ltd was ₹627 Cr.
₹-3.00
(
